In the Claims

1. (Currently Amended) A method of promoting tissue repair wherein extracellular matrix of the tissue has been degraded comprising administering an antibody, which modulates function of beta 1 integrin, to a tissue wherein extracellular matrix of the tissue has been degraded in need of repair, wherein the antibody binds to the beta 1 integrin molecule in a region of amino acid residues 82 to 87 comprising residues TAEKLK (SEQ ID NO: 1) of the sequence of the mature beta 1 integrin molecule, and functional modulation of beta 1 integrin results in at least one of (i) an inhibition of the apoptotic pathway, (ii) an alteration in the metalloproteinase balance and or (iii) an increase in the anabolism of the extracellular matrix.

2.-15. (Cancelled)

- 16. (Previously Presented) The method according to claim 1, wherein the antibody is a monoclonal antibody produced by the commercial clone JB1a.
- 17.-19. (Cancelled).
- 20. (Previously Presented) The method of claim 1, wherein the antibody is a humanized antibody, a chimeric antibody or a human antibody.
- 21. (Previously Presented) The method of claim 1, wherein the antibody is a fragment of the monoclonal antibody produced by the commercial clone JB1a.
- 22. (Previously Presented) The method of claim 1, wherein the functional modulation causes shedding of the beta 1 integrin.
- 23. (Previously Presented) The method of claim 1, wherein the alteration in the metalloprotein ase balance results in at least one of (i) an increase in inactive MMP9, and (ii) a decrease in MMP1.

- 24. (Previously Presented) The method of claim 1, where functional modulation further includes an increase in TIMP1.
- 25. (Cancelled)
- 26. (Currently Amended) The method of claim 1, wherein promotion of tissue repair <u>treats</u> is for treating lung emphysema.
- 27. (Currently Amended) The method of claim 1, wherein promotion of tissue repair <u>treats</u> is for treating chronic obstructive pulmonary disease (COPD).
- 28.-30. (Cancelled)
- 31. (Previously Presented) The method of claim 1, wherein the tissue to be repaired is selected from at least one of the group consisting of skin tissue, tissue of the central nervous system, liver tissue, kidney tissue, tissue of the cardiovascular system, bone tissue and cartilage.
- 32. (Previously Presented) The method of claim 31, wherein the tissue is tissue of the central nervous system.
- 33. (Previously Presented) The method of claim 16, wherein promotion of tissue repair treats chronic obstructive pulmonary disease (COPD).
- 34. (Previously Presented) The method of claim 33, wherein the chronic obstructive pulmonary disease (COPD) is lung emphysema.
- 35. (New) The method of claim 1, wherein the antibody is administered to tissue which is in need of regeneration.